磷酸化前整合位點蛋白1抗體品牌 英文名稱  Anti-Phospho-PIM1(Tyr218)

中文名稱  磷酸化前整合位點蛋白1抗體品牌 

別    名 Oncogene PIM 1; Oncogene PIM1; PIM 1; Pim 1 kinase; Pim 1 oncogene; PIM; Pim2; PIM3; Proto oncogene serine/threonine protein kinase Pim 1; Proviral integration site 1; Proviral integration site 2.

產(chǎn)品屬性：

濃    度  1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應   Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep

產(chǎn)品類型   一抗 磷酸化抗體  

研究領域     免疫學 信號轉(zhuǎn)導 細胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶

蛋白分子量  predicted molecular weight: 45kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated Synthesised phosphopeptide derived from human PIM1 around the phosphorylation site of Tyr218

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化前整合位點蛋白1抗體品牌 產(chǎn)品應用   WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 PIM1 is a member of the serine/threonine kinase PIM oncogene family. PIM1 has been implicated in lymphomagenesis, cell proliferation, apoptosis, differentiation and tumourigenesis. The PIM1 protein kinase is upregulated in prostate cancer.

Function : Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerced by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.

Subunit : Isoform 2 is isolated as a monomer whereas isoform 1 complexes with other proteins. Binds to RP9. Isoform 1, but not isoform 2, binds BMX. Isoform 2 interacts with CDKN1B and FOXO3. Interacts with BAD. Interacts with PPP2CA; this interaction promotes dephosphorylation of PIM1, ubiquitination and proteasomal degradation. Interacts with HSP90, this interaction stabilizes PIM1 protein levels. Interacts (ubiquitinated form) with HSP70 and promotes its proteosomal degradation. Interacts with CDKN1A. Interacts with CDC25C. Interacts (via N-terminal 96 residues) with CDC25A. Interacts with MAP3K5. Interacts with MYC.

Subcellular Location : Isoform 2: Cytoplasm. Nucleus. Isoform 1: Cell membrane.

Post-translational modifications : Autophosphorylated on both serine/threonine and tyrosine residues. Phosphorylated. Interaction with PPP2CA promotes dephosphorylation.

Ubiquitinated, leading to proteasomal degradation.

Similarity : Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. PIM subfamily.

Contains 1 protein kinase domain.

Database links : UniProtKB/Swiss-Prot: P11309.3

PIM1蛋白是絲氨酸/蘇氨酸蛋白激酶2家族成員，他參與細胞信號轉(zhuǎn)導、細胞凋亡、轉(zhuǎn)錄調(diào)節(jié)，在很多中表達，尤其是，表達水平較高。

實驗流程：

全、新、優(yōu)、品、好四大特點：

磷酸化前整合位點蛋白1抗體品牌 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標準品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團隊，產(chǎn)品一旦售出，實驗過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時沒有任何的后顧之憂。

正在熱銷的相關產(chǎn)品：

Anti-CD27/TNFRSF7/FITC 熒光素標記CD27抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-Hrasls3/HREV107/FITC 熒光素標記HRAS樣抑制因子3抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh CDAN1 先天性紅細胞生成異常性蛋白1抗體 規(guī)格 0.2ml

Polycystin 1(Polycystic Kidney Disease 1) 蛋白1抗原 0.5mg

IFIT5 英文名稱： 干擾素誘導的三角形四肽重復蛋白5抗體 0.2ml

Rhesus antibody Rh TCF3/E2A/E47 轉(zhuǎn)錄因子3抗體(螺旋環(huán)螺旋蛋白HE47) 規(guī)格 0.2ml

Anti-Hrasls3/HREV107/FITC 熒光素標記HRAS樣抑制因子3抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Human Immunoglobulin M,IgM ELISA Kit 人免疫球蛋白MMulti-class antibodies規(guī)格： 48T

Anti-phospho-RUNX1/AML1(Ser249) 磷酸化急性髓細胞1蛋白抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh GRM2/GLUR2 促代謝型谷氨酸受體2抗體 規(guī)格 0.1ml

CEA/CD66(Human carcinoembryonic antign) ELISA Kit 人癌胚抗原 96T

1-Oct 英文名稱： 陽離子轉(zhuǎn)運器1抗體 0.1ml

phospho-Band3 (Tyr359) 英文名稱： 磷酸化紅細胞陰離子交換蛋白1抗體 0.1ml

Anti-phospho-RUNX1/AML1(Ser249) 磷酸化急性髓細胞1蛋白抗體Multi-class antibodies規(guī)格： 0.1ml

GAL ELISA Kit 大鼠甘丙肽/甘丙素Multi-class antibodies規(guī)格： 48T

Anti-Phospho-Tie2 (Ser1119) 磷酸化生成素受體2抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh glypican 3/GPC3 磷脂?；嫉鞍拙厶?3抗體 規(guī)格 0.1ml

MUC5B(Human mucin-5 subtype B) ELISA kit 人粘蛋白/粘液素5B 96T

phospho-NIFK (Thr230) 英文名稱： 磷酸化NIFK抗體 0.1ml

Annexin VI 英文名稱： 膜粘連蛋白6抗體 0.1ml

Anti-Phospho-Tie2 (Ser1119) 磷酸化生成素受體2抗體Multi-class antibodies規(guī)格： 0.1ml

CL-0087H4(人)5×106cells/瓶×2

IgG2 Others Human 人 IgG2-Fc (257 Ser/Ala) 人細胞裂解液 (陽性對照)

小鼠直腸平滑肌細胞完全培養(yǎng)基 100mL

SV40 MES 13小鼠腎小球系膜細胞 SV40 MES 13 in mouse glomerular mesangial cells DMEM培養(yǎng)基+5%FBS

CF Protein Rat 重組大鼠 CF / Ciliary Neuroophic Factor 蛋白

SC-1(小鼠胚胎細胞) 5×106cells/瓶×2 K562(慢性髓原)

CL-0084FRhK-4(恒河猴胚腎細胞)5×106cells/瓶×2

FAS Others Rat 大鼠 FAS / CD95 / APO-1 / TNFRSF6 人細胞裂解液 (陽性對照)

人平滑肌細胞裂解物HBVSMCL

HO-8910細胞，人細胞 小鼠淋巴結(jié)上皮樣細胞,SVEC4-10細胞 腎動脈內(nèi)皮細胞Many types of cells包裝：5 × 105次方(1ml)

COLO 320DM(人結(jié)直腸腺癌細胞) 5×106cells/瓶×2

HNEpC Pellet 人鼻粘膜上皮細胞團塊 > 1 mio.cells 人食道上皮細胞cDNAHEEpiC cDNA

磷酸化前整合位點蛋白1抗體品牌 IGFBP6 Others Mouse 小鼠 IGFBP6 / IBP-6 人細胞裂解液 (陽性對照)

人真皮成纖維細胞-新生兒裂解物HDF-n L

C2C12 小鼠成肌細胞

CL-0110HL-60(人早幼粒急性細胞)5×106cells/瓶×2

人羊膜間充質(zhì)基質(zhì)細胞

人胚腎細胞(SV40T基因修飾);293T/17 人主動脈內(nèi)皮細胞完全培養(yǎng)基 100mL

技術(shù)外包服務:

★磷酸化前整合位點蛋白1抗體品牌 分子生物學：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學：基因合成、引物合成、基因測序、載體構(gòu)建等

★蛋白工程：原核、哺乳動物蛋白表達系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細胞工程：細胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復、克隆形成)、細胞培養(yǎng)、細胞膜制備、穩(wěn)定細胞株構(gòu)建、細胞RNAi技術(shù)等等。